AU1626199A - A vi-repa conjugate vaccine for immunization against salmonella typhi - Google Patents
A vi-repa conjugate vaccine for immunization against salmonella typhiInfo
- Publication number
- AU1626199A AU1626199A AU16261/99A AU1626199A AU1626199A AU 1626199 A AU1626199 A AU 1626199A AU 16261/99 A AU16261/99 A AU 16261/99A AU 1626199 A AU1626199 A AU 1626199A AU 1626199 A AU1626199 A AU 1626199A
- Authority
- AU
- Australia
- Prior art keywords
- salmonella typhi
- conjugate vaccine
- immunization against
- against salmonella
- repa conjugate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 108010060123 Conjugate Vaccines Proteins 0.000 title 1
- 241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 title 1
- 229940031670 conjugate vaccine Drugs 0.000 title 1
- 230000003053 immunization Effects 0.000 title 1
- 238000002649 immunization Methods 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US1998/025746 WO2000033882A1 (en) | 1998-12-04 | 1998-12-04 | A vi-repa conjugate vaccine for immunization against salmonella typhi |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU1626199A true AU1626199A (en) | 2000-06-26 |
Family
ID=22268424
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU16261/99A Abandoned AU1626199A (en) | 1998-12-04 | 1998-12-04 | A vi-repa conjugate vaccine for immunization against salmonella typhi |
Country Status (2)
| Country | Link |
|---|---|
| AU (1) | AU1626199A (en) |
| WO (1) | WO2000033882A1 (en) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7082569B2 (en) | 2001-01-17 | 2006-07-25 | Outlooksoft Corporation | Systems and methods providing dynamic spreadsheet functionality |
| PL2878307T3 (en) † | 2005-06-27 | 2020-01-31 | Glaxosmithkline Biologicals S.A. | Immunogenic composition |
| GB0714963D0 (en) | 2007-08-01 | 2007-09-12 | Novartis Ag | Compositions comprising antigens |
| NZ584683A (en) | 2007-10-19 | 2012-05-25 | Novartis Ag | Neisseria meningitidis serogroup B vaccine formulations |
| US9579372B2 (en) | 2008-02-21 | 2017-02-28 | Glaxosmithkline Biologicals Sa | Meningococcal fHBP polypeptides |
| AU2009309416B2 (en) | 2008-10-27 | 2015-05-28 | Glaxosmithkline Biologicals S.A. | Purification method |
| GB0822633D0 (en) | 2008-12-11 | 2009-01-21 | Novartis Ag | Formulation |
| ES2797504T3 (en) | 2009-03-24 | 2020-12-02 | Glaxosmithkline Biologicals Sa | Meningococcal factor H binding protein used as adjuvant |
| BRPI1009829A2 (en) | 2009-03-24 | 2016-11-16 | Novartis Ag | meningococcal h-factor binding protein combinations and pneumococcal saccharide conjugates |
| CA2758490C (en) | 2009-04-14 | 2023-05-02 | Novartis Ag | Compositions for immunising against staphylococcus aureus |
| BR112012004275A2 (en) | 2009-08-27 | 2016-11-16 | Novartis Ag | hybrid polypeptides including meningococcal fhbp sequences |
| US20120237536A1 (en) | 2009-09-10 | 2012-09-20 | Novartis | Combination vaccines against respiratory tract diseases |
| WO2011039631A2 (en) | 2009-09-30 | 2011-04-07 | Novartis Ag | Expression of meningococcal fhbp polypeptides |
| EP2493499A1 (en) | 2009-10-27 | 2012-09-05 | Novartis AG | Modified meningococcal fhbp polypeptides |
| GB0919690D0 (en) | 2009-11-10 | 2009-12-23 | Guy S And St Thomas S Nhs Foun | compositions for immunising against staphylococcus aureus |
| GB201003333D0 (en) | 2010-02-26 | 2010-04-14 | Novartis Ag | Immunogenic proteins and compositions |
| GB201005625D0 (en) | 2010-04-01 | 2010-05-19 | Novartis Ag | Immunogenic proteins and compositions |
| AU2011268507B2 (en) | 2010-06-25 | 2014-08-14 | Novartis Ag | Combinations of meningococcal factor H binding proteins |
| GB201101665D0 (en) | 2011-01-31 | 2011-03-16 | Novartis Ag | Immunogenic compositions |
| EP2667852B1 (en) | 2011-01-27 | 2016-11-09 | GlaxoSmithKline Biologicals SA | Adjuvant nanoemulsions with crystallisation inhibitors |
| US20140112950A1 (en) | 2011-03-02 | 2014-04-24 | Manmohan Singh | Combination vaccines with lower doses of antigen and/or adjuvant |
| US10357568B2 (en) | 2011-03-24 | 2019-07-23 | Glaxosmithkline Biologicals S.A. | Adjuvant nanoemulsions with phospholipids |
| GB201114923D0 (en) | 2011-08-30 | 2011-10-12 | Novartis Ag | Immunogenic proteins and compositions |
| CN103917245B (en) | 2011-09-14 | 2017-06-06 | 葛兰素史密丝克莱恩生物有限公司 | Method for preparing glycoprotein glycoconjugate |
| JP6170932B2 (en) | 2011-11-07 | 2017-07-26 | ノバルティス アーゲー | Carrier molecule comprising spr0096 antigen and spr2021 antigen |
| GB201121301D0 (en) | 2011-12-12 | 2012-01-25 | Novartis Ag | Method |
| JP2015505309A (en) | 2011-12-29 | 2015-02-19 | ノバルティス アーゲー | Adjuvanted combination of meningococcal factor H binding protein |
| JP2015510872A (en) | 2012-03-07 | 2015-04-13 | ノバルティス アーゲー | Enhanced formulation of Streptococcus pneumoniae antigen |
| RU2015106930A (en) | 2012-09-06 | 2016-10-20 | Новартис Аг | COMBINED VACCINES WITH THE MENINGOCOCC SEROGRAPH B AND K / D / S |
| SG11201500978TA (en) | 2012-10-03 | 2015-07-30 | Glaxosmithkline Biolog Sa | Immunogenic compositions |
| JP6340011B2 (en) | 2012-11-30 | 2018-06-06 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | Pseudomonas antigens and antigen combinations |
| TR201807340T4 (en) | 2013-02-01 | 2018-06-21 | Glaxosmithkline Biologicals Sa | Intradermal administration of immunological compositions comprising bell-like receptor agonists. |
| WO2015029056A1 (en) | 2013-08-24 | 2015-03-05 | Bharat Biotech International Limited | A bacterial vaccine and methods for manufacture thereof |
| CA2940447C (en) | 2014-02-28 | 2023-07-11 | Glaxosmithkline Biologicals Sa | Modified meningococcal fhbp polypeptides |
| EP3439704A1 (en) | 2016-04-05 | 2019-02-13 | GSK Vaccines S.r.l. | Immunogenic compositions |
| EP3448424A4 (en) * | 2016-04-25 | 2019-10-02 | National Institute of Immunology | NOVEL CONJUGATE FOR TYPHOID VACCINATION COMPRISING A CHEMICAL CONJUGATE OF POLYSACCHARIDE VI AND FLAGELLIN, METHOD FOR PRODUCING THE SAME, AND COMPOSITION COMPRISING THE CONJUGATE |
| CN106990188B (en) * | 2017-06-09 | 2019-11-15 | 齐齐哈尔医学院 | A high-performance liquid chromatography detection method for Pseudomonas aeruginosa exotoxin A |
| EP3607967A1 (en) | 2018-08-09 | 2020-02-12 | GlaxoSmithKline Biologicals S.A. | Modified meningococcal fhbp polypeptides |
| GB202208093D0 (en) | 2022-06-01 | 2022-07-13 | Glaxosmithkline Biologicals Sa | Immunogenic composition |
| GB202208089D0 (en) | 2022-06-01 | 2022-07-13 | Glaxosmithkline Biologicals Sa | Immunogenic composition |
-
1998
- 1998-12-04 WO PCT/US1998/025746 patent/WO2000033882A1/en not_active Ceased
- 1998-12-04 AU AU16261/99A patent/AU1626199A/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2000033882A1 (en) | 2000-06-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU1626199A (en) | A vi-repa conjugate vaccine for immunization against salmonella typhi | |
| AU4781297A (en) | Vaccines | |
| AU2120197A (en) | Salmonella typhimurium vaccine | |
| AU4070097A (en) | Mucosal immunogens for novel vaccines | |
| HUP9601466A2 (en) | Adjuvants for viral vaccines | |
| AU2001258279A1 (en) | Adjuvant for vaccines | |
| HUP9601462A2 (en) | Adjuvants for viral vaccines | |
| HUP9701586A3 (en) | Improved inactivated vaccines | |
| AU3154395A (en) | Contraceptive vaccine | |
| AU2769595A (en) | Contraceptive vaccine | |
| AU1420897A (en) | Conjugate vaccine for (salmonella paratyphi) a | |
| ZA9711565B (en) | Vaccine | |
| AU1144197A (en) | Salmonella vaccines | |
| GB9611673D0 (en) | Meningococcal vaccine | |
| PL330863A1 (en) | Recombination vaccine against diseases caused by encysted organisms | |
| IL143808A0 (en) | Oral vaccine against diarrhea | |
| GB9704977D0 (en) | FIV vaccine | |
| PL346645A1 (en) | IMMUNOGENIC β-PROPIONAMIDO-LINKED POLYSACCHARIDE PROTEIN CONJUGATE USEFUL AS A VACCINE PRODUCED USING AN N-ACRYLOYLATED POLYSACCHARIDE | |
| AU5739999A (en) | Salmonella typhi vaccine compositions | |
| IL109519A0 (en) | Vaccines for oral immunization against infecting agents | |
| AU8877998A (en) | Oral vaccine | |
| AU3360797A (en) | Vaccine against gastro-intestinal nematodes | |
| AUPM370894A0 (en) | Improved adjuvant for vaccines | |
| HK1042041A (en) | Oral vaccine against diarrhea | |
| TJ307B (en) | A method for the preparation of a anti - theileriosis vaccine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK6 | Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase |